Hustler's MicroGrant

The City of Oxford has created a new funding opportunity for businesses in Oxford that provides capital for up to $2,500 or 50% of costs for projects that improve sustainability and/or building facades.

The National Library of Medicine (NLM) supports innovative research and development in biomedical informatics and data science. This funding opportunity focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and personal wellness to ensure the research is scalable, reproducible, and generalizable. The scope of NLM's interest in these research domains is broad, with emphasis on new and innovative methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, scalable, and reusable approaches to discovery, curation, analysis, organization, and management of health-related data and digital objects.

REDC offers grants of up to $5,000 for qualifying for-profit New Hampshire businesses with five or fewer employees to purchase equipment or machinery. Grant funding is limited and not guaranteed.

The Innovate Alabama Supplemental Grant Program provides additional resources for small businesses whose proven business models and technologies are helping accelerate innovation in the state. Small businesses who have an active Phase I or Phase II Federal Small Business Innovation Research (SBIR) or Small Business Technology Transfer (STTR) grant are eligible for non-dilutive funding from the Innovate Alabama Supplemental Grant Program. This unique grant program provides support for recipients who do not need to exchange shares of their company for the grant. These businesses have proven through scientific review that their technologies are viable, valuable and scalable.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.